Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;7(8):914-923.
doi: 10.1530/EC-18-0172. Epub 2018 Jul 5.

Adherence and long-term growth outcomes: results from the easypod™ connect observational study (ECOS) in paediatric patients with growth disorders

Ekaterina Koledova  1 , George Stoyanov  1 , Leroy Ovbude  2 , Peter S W Davies  3
Affiliations

Adherence and long-term growth outcomes: results from the easypod™ connect observational study (ECOS) in paediatric patients with growth disorders

Ekaterina Koledova et al. Endocr Connect. 2018 Aug.

Abstract

Objective: The easypod connect observational study (ECOS) assessed treatment adherence among paediatric patients receiving growth hormone (GH) via the easypod electronic injection device.

Design: ECOS was an open-label, observational, longitudinal study conducted in 24 countries between 2010 and 2016, enrolling children treated with GH.

Methods: The primary endpoint was the rate of treatment adherence during 5 years of follow-up. Impact of adherence on growth outcomes was assessed using Spearman's product-moment correlations.

Results and conclusions: Overall, 1190 patients had easypod data available for ≥3 months; most patients had GH deficiency (75%); 606 of these patients were GH naïve at baseline. Over the first year of monitoring, the median rate of adherence was 93.7% among patients overall and >93.0% in GH-naïve patients, irrespective of the treatment indication. Clinically meaningful improvements in growth rates were observed after 1 year of treatment across all GH indications. Adherence decreased with increasing treatment duration, but the overall median adherence rate remained high after 3 years of follow-up: 87.2% (n = 409), 75.5% after 4 years (n = 143) and 70.2% after 5 years (n = 43). Statistically significant correlations between adherence and 1-year change in height standard deviation score (P < 0.001 for patients overall) and height velocity (P < 0.001) were observed.

Conclusions: ECOS produced accurate, real-time adherence data in a large population of GH-treated children over 5 years of follow-up. Using the easypod connect system, physicians can potentially identify patients with inadequate adherence and poor response to treatment, enabling them to take appropriate action to help them maximise the benefits of GH treatment.

Keywords: GH treatment; adherence; e-Health; easypod.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment adherence rates over time in the easypod adherence data analysis set (A) overall (n = 1190) and (B) the GH-naïve patients (n = 608). Boxes show Q1 and Q3, with median as white line and mean as red squares.
Figure 2
Figure 2
The proportion of patients treated with GH using ‘easypod’ with adherence rates of at least 80% at each year over the 5-year study period and for all patients at any time within the 5-year period.
See this image and copyright information in PMC

References

    1. Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, Welch K, Bryant J. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technology Assessment 2010. 14 1–209, iii–iv. (10.3310/hta14420) - DOI - PubMed
    1. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Hormone Research in Paediatrics 2016. 86 361–397. (10.1159/000452150) - DOI - PubMed
    1. Richmond E, Rogol AD. Current indications for growth hormone therapy for children and adolescents. Endocrine Development 2010. 18 92–108. - PubMed
    1. Ranke M, Lindberg A, Cowell C, Wikland K, Reiter E, Wilton P, Price D. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). Journal of Clinical Endocrinology and Metabolism 2003. 88 125–131. (10.1210/jc.2002-020867) - DOI - PubMed
    1. Sas TC, de Ridder MA, Wit JM, Rotteveel J, Oostdijk W, Reeser HM, Otten BJ, de Muinck Keizer-Schrama SM. Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. Hormone Research in Paediatrics 2010. 74 172–181. (10.1159/000281323) - DOI - PubMed

LinkOut - more resources